These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

82 related items for PubMed ID: 872116

  • 1. Biochemically detectable tumor markers in urine of bladder cancer patients.
    Irving CC.
    Cancer Res; 1977 Aug; 37(8 Pt 2):2872-4. PubMed ID: 872116
    [Abstract] [Full Text] [Related]

  • 2. Nucleoside excretion in breast cancer: comparison with other biochemical tumour-index-substances.
    Coombes RC, Powles TJ, Gehrke CW, Waalkes TP, Neville AM.
    Invest Cell Pathol; 1979 Aug; 2(1):11-4. PubMed ID: 511604
    [Abstract] [Full Text] [Related]

  • 3. Urinary pseudouridine and beta-aminoisobutyric acid in patients with low grade urothelial tumours. Relations between excretion and tumour recurrence.
    Nyholm KK, Sjolin KE, Wolf H, Hammer M, Knudsen J, Stahl D, Nielsen HR.
    Biomedicine; 1976 May; 25(3):85-7. PubMed ID: 949520
    [Abstract] [Full Text] [Related]

  • 4. A study on the clinical significance of urinary beta-aminoisobutyric acid in patients with urothelial tumours.
    Nyholm KK, Sjölin KE, Hammer M, Knudsen J, Stahl D, Nielsen HR.
    Biomedicine; 1975 Nov; 22(6):509-16. PubMed ID: 1225382
    [Abstract] [Full Text] [Related]

  • 5. Excretion patterns of pseudouridine and beta-aminoisobutyric acid in patients with tumours of the upper urinary tract.
    Kvist E, Sjølin KE, Iversen J.
    Scand J Urol Nephrol; 1990 Nov; 24(4):287-92. PubMed ID: 2274753
    [Abstract] [Full Text] [Related]

  • 6. A quantitative approach to determining disease response during therapy using multiple biologic markers: application to carcinoma of the breast.
    Woo KB, Waalkes TP, Ahmann DL, Tormey DC, Gehrke CW, Oliverio VT.
    Cancer; 1978 May; 41(5):1685-703. PubMed ID: 348295
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. A diagnostic-prognostic test for bladder cancer using a monoclonal antibody-based enzyme-linked immunoassay for detection of urinary fibrin(ogen) degradation products.
    McCabe RP, Lamm DL, Haspel MV, Pomato N, Smith KO, Thompson E, Hanna MG.
    Cancer Res; 1984 Dec; 44(12 Pt 1):5886-93. PubMed ID: 6498846
    [Abstract] [Full Text] [Related]

  • 10. Pseudouridine and beta-aminoisobutyric acid excretion in urine: diagnostic and prognostic value.
    Kvist E, Sjølin KE.
    Scand J Urol Nephrol; 1990 Dec; 24(4):283-5. PubMed ID: 2274752
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. The urinary excretion of nucleosides of ribonucleic acid by patients with advanced cancer.
    Waalkes TP, Gehrke CW, Zumwalt RW, Chang SY, Lakings DB, Tormey DC, Ahmann DL, Moertel CG.
    Cancer; 1975 Aug; 36(2):390-8. PubMed ID: 1157009
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Urine based markers of urological malignancy.
    Konety BR, Getzenberg RH.
    J Urol; 2001 Feb; 165(2):600-11. PubMed ID: 11176445
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 5.